medigraphic.com
ISSN 1561-302X (Print)

2022, Number 4

<< Back Next >>

Rev cubana med 2022; 61 (4)

Cardiometabolic risk in patients with uncomplicated essential arterial hypertension

León ÁJL, Ventura CA, Gutiérrez RÁR

Language: Spanish
References: 32
Page: 1-14
PDF size: 421.87 Kb.


ABSTRACT

Introduction: Cardiometabolic risk assessment in patients with essential arterial hypertension is vital and a diagnostic challenge.
Objective: To evaluate the behavior of cardiometabolic risk in patients with uncomplicated essential hypertension.
Methods: A descriptive, cross-sectional study was carried out in 100 hypertensive patients without target organ damage who underwent clinical history, glycemia, glycosylated hemoglobin, lipidogram and uric acid. They were correlated with body mass index, time of evolution of arterial hypertension and global cardiovascular risk.
Results: Of the patients, 56% were men, 31% were smokers, 83% were overweight and obese, 86% were sedentary, 71% did not have a healthy diet and 53% had been hypertensive for more than 5 years. In the obese, a significant relationship was found with abdominal circumference (110.9 ± 8.9, p=0.000), triglycerides (1.8 ± 0.9, p=0.000) and uric acid (374 ± 100.7, p=0.001). Age (62.9 ± 7.8, p=0.000), systolic blood pressure (151.6±15.6, p=0.021), lower HDL (0.9±0.3, p=0.000) and uric acid (349, 3 ± 115.3, p=0.015) were significantly related to high cardiovascular risk.
Conclusions: The results demonstrated the value of clinical parameters such as age, abdominal circumference, body mass index and systolic blood pressure, as well as metabolic parameters such as triglycerides, HDL and uric acid in the evaluation of cardiometabolic risk and its relationship with cardiovascular risk in hypertensive patients.


REFERENCES

  1. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart Disease and Stroke Statistics-2018. A Report From the American Heart Association. Circulation. 2018;137(12):e67-e492. DOI: https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000558?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org1.

  2. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 [acceso: 20/02/2022];42(34):3227-337. Disponible en: https://academic.oup.com/eurheartj/article/42/34/3227/6358713?login=false2.

  3. Bonet Gorbea M, Varona Pérez P. III Encuesta nacional de factores de riesgo y actividades preventivas de enfermedades no trasmisibles. Cuba 2010-2011. Editorial Ciencias Médicas 2014 [acceso: 20/02/2022]. Disponible en: http://www.bvs.sld.cu/libros/encuesta_nacional_riesgo/indice_p.htm3.

  4. Pérez Caballero MD, León Álvarez JL, Dueñas Herrera A, Alfonzo Guerra JP, Navarro Despaigne DA, De la Noval García R, et al. Hipertensión arterial. Guía para el diagnóstico, evaluación y tratamiento. 2018. [acceso: 20/02/2022]. ISBN 978-959-313-643-3. Disponible en: http://www.bvscuba.sld.cu/libro/hipertension-arterial-guia-para-el-diagnostico-evaluacion-y-tratamiento/4.

  5. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev. Nephrol. 2020 [acceso: 20/02/2022];(4):223-37. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998524/5.

  6. Mulè G, Calcaterra I, Nardi E, Cerasola G, Cottone S. Metabolic syndrome in hypertensive patients: An unholy alliance. World J Cardiol. 2014 [acceso: 18/02/2022];6(9):890-907. Disponible en: https://www.wjgnet.com/1949-8462/full/v6/i9/890.htm6.

  7. Srikanthan K, Feyh A, Visweshwar H, Shapiro JI, Sodhi K. Systematic Review of Metabolic Syndrome Biomarkers: A Panel for Early Detection, Management, and Risk Stratification in the West Virginian Population. Int J Med Sci. 2016 [acceso: 18/02/2022];13(1):25-38. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716817/7.

  8. Liu J, Chen Y, Cai K, Gong Y. Association of metabolic syndrome with cardiovascular outcomes in hypertensive patients: a systematic review and meta-analysis. J Endocrinol Invest. 2021 [acceso: 18/02/2022];44(11):2333-40. Disponible en: https://link.springer.com/article/10.1007/s40618-021-01603-78.

  9. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018 [acceso: 18/02/2022];36(10):1953-2041. Disponible en: https://journals.lww.com/jhypertension/Fulltext/2018/10000/2018_ESC_ESH_Guidelines_for_the_management_of.2.aspx9.

  10. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmel farb C, et al. 2017ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 [acceso: 20/01/2022];71(6):e13-e115. Disponible en: https://www.ahajournals.org/doi/full/10.1161/HYP.0000000000000065?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org10.

  11. Kario K, Shin J, Chen CH, Buranakitjaroen P, Chia YC, Divinagracia R, et al. Expert panel consensus recommendations for ambulatory blood pressure monitoring in Asia: the HOPE Asia Network. J Clin Hypertens (Greenwich) 2019;(9):1250-83. DOI: https://onlinelibrary.wiley.com/doi/10.1111/jch.1365211.

  12. Stergiou GS, O'Brien E, Myers M, Palatini P, Parati G, STRIDE BP Scientific Advisory Board. STRIDE BP: an international initiative for accurate blood pressure measurement. J Hypertens. 2020 [acceso: 20/01/2022];38(3):395-9. Disponible en: https://journals.lww.com/jhypertension/Abstract/2020/03000/STRIDE_BP__an_international_initiative_for.4.aspx12.

  13. Nduka CU, Stranges S, Sarki AM, Kimani PK, Uthman OA. Evidence of increased blood pressure and hypertension risk among people living with HIV on antiretroviral therapy: a systematic review with meta-analysis. J Hum Hypertens 2016 [acceso: 20/01/2022];(6):355-62. Disponible en: https://www.nature.com/articles/jhh20159713.

  14. Plummer C, Michael A, Shaikh G, Stewart M, Buckley L, Miles T, et al. Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK. Br J Cancer. 2019 [acceso: 20/01/2022];121(2):109-16. Disponible en: https://www.nature.com/articles/s41416-019-0481-y14.

  15. Alberti K, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;;120(16):1640-5. DOI: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.109.192644?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed15.

  16. Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 2018 [acceso: 20/01/2022];6(6):464-75. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966620/16.

  17. Calderín Bouza RO, Yanes Quesada MA, León Álvarez JL, Bacallao Gallestey J, Yanes Quesada M, Jiménez Paneque R, et al. Propuesta de clasificación cubana para el estudio del síndrome de insulinorresistencia en pacientes dislipidémicos. Acta Médica 2018 [acceso: 20/01/2022];19(1): Disponible en: https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=7860317.

  18. Sinnott SJ, Tomlinson LA, Root AA, Mathur R, Mansfield KE, Smeeth L, et al. Comparative effectiveness of fourth-line anti-hypertensive agents in resistant hypertension: a systematic review and meta-analysis. Eur J Prev Cardiol .2017 [acceso: 20/01/2022];(3):228-38. Disponible en: https://academic.oup.com/eurjpc/article/24/3/228/5926649?login=false18.

  19. Krieger EM, Drager LF, Giorgi DMA, Pereira AC, Barreto-Filho JAS, Nogueira AR, et al. ReHOT Investigators. Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT Randomized Study (Resistant Hypertension Optimal Treatment). Hypertension 2018;71(4):681-90. DOI: https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.117.10662?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed19.

  20. García Sánchez N, León Álvarez JL. Biomarcadores de la arteriosclerosis como predictores del riesgo cardiovascular en la hipertensión arterial no complicada. RCAN Rev Cuban Aliment Nutr 2016 [acceso: 20/01/2022];26(2):275-83. Disponible: http://www.revalnutricion.sld.cu/index.php/rcan/article/view/6720.

  21. Rho YH, Woo JH, Choi SJ, Lee YH, Ji JD, Song GG. Association between serum uric acid and the Adult Treatment Panel III-defined metabolic syndrome: results from a single hospital database. Metabolism. 2008 [acceso: 20/01/2022];57(1):71-6. Disponible en: https://pubmed.ncbi.nlm.nih.gov/18078861/21.

  22. 27. Maloberti A, Giannattasio C, Bombelli M, Desideri G, Cicero AFG, Muiesan ML, et al. Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for Heart Health) Project. High Blood Press Cardiovasc Prev. 2020 [acceso: 20/01/2022];27(2):121-8. Disponible en: https://link.springer.com/article/10.1007/s40292-020-00368-z22. 27.

  23. Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, et al. Hypertension Canada. Hypertension Canada's 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children. Can J Cardiol 2018 [acceso: 18/01/2022];34(5):506-25. https://pubmed.ncbi.nlm.nih.gov/29731013/ 23.

  24. Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res 2019 [acceso: 20/01/2022];42(9):1235-481. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31375757/24.

  25. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 [acceso: 20/01/2022];74(10)):1376-414. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344373/25.

  26. León Álvarez JL, García Sánchez N, Gutiérrez Rojas A, Pérez Caballero MD. Biomarcadores de daño renal en la hipertensión arterial esencial. Rev. Cub. Med. 2016 [acceso: 20/01/2022];55(4). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-7523201600040000426.

  27. Vongpatanasin W. Resistant hypertension: a review of diagnosis and management. JAMA 2014 [acceso: 20/01/2022];311(21):2216-24. Disponible en: https://jamanetwork.com/journals/jama/article-abstract/187718927.

  28. Ayala DE, Hermida RC, Mojon A, Fernández JR. Cardiovascular risk of resistant hypertension: dependence on treatment-time regimen of blood pressure-lowering medications. Chronobiol Int 2013;30(1-2):340-52. DOI: https://www.tandfonline.com/doi/abs/10.3109/07420528.2012.701455?journalCode=icbi2028.

  29. Bhatt H, Siddiqui M, Judd E, Oparil S, Calhoun D. Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement. J Am Soc Hypertens 2016 [acceso: 20/01/2022];10(6):493-9. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905807/29.

  30. Jager RL de, Van Maarseveen EM, Bots ML, Blankestijn PJ, SYMPATHY investigators. Medication adherence in patients with apparent resistant hypertension: Findings from the SYMPATHY trial. Br J Clin Pharmacol 2018;84(1):18-24. DOI: https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.1340230.

  31. Roush GC, Fagard RH, Salles GF, Pierdomenico SD, Reboldi G, Verdecchia P, et al. Prognostic impact from clinic, daytime, and nighttime systolic blood pressure in 9 cohorts on 13,844 patients with hypertension. J Hypertens 2014 [acceso: 20/01/2022];32(12):2332-40. Disponible en: Disponible en: https://journals.lww.com/jhypertension/Abstract/2014/12000/Prognostic_impact_from_clinic,_daytime,_and.6.aspx 31.

  32. Hermida RC, Crespo JJ, Otero A, Domínguez-Sardiña M, Moyá A, Ríos MT, et al. Asleep blood pressure: significant prognostic marker of vascular risk and therapeutic target for prevention. Eur Heart J 2018 [acceso: 20/01/2022];39(47):4159-71. Disponible en: https://academic.oup.com/eurheartj/article/39/47/4159/5070409?login=false32.




2020     |     www.medigraphic.com